Rice Hall James & Associates LLC Cuts Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Rice Hall James & Associates LLC trimmed its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 58,968 shares of the specialty pharmaceutical company’s stock after selling 1,407 shares during the period. Rice Hall James & Associates LLC owned about 0.28% of ANI Pharmaceuticals worth $3,260,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. KBC Group NV boosted its holdings in ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after purchasing an additional 600 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in ANI Pharmaceuticals by 24.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares in the last quarter. HighTower Advisors LLC acquired a new position in ANI Pharmaceuticals in the third quarter valued at approximately $222,000. China Universal Asset Management Co. Ltd. boosted its holdings in ANI Pharmaceuticals by 64.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,045 shares of the specialty pharmaceutical company’s stock valued at $241,000 after purchasing an additional 1,582 shares in the last quarter. Finally, James Investment Research Inc. acquired a new position in ANI Pharmaceuticals in the third quarter valued at approximately $243,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ANIP. StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. Truist Financial upped their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. HC Wainwright reissued a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Finally, Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $77.71.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $58.82 on Wednesday. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The stock has a fifty day moving average price of $56.98 and a 200 day moving average price of $58.23. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $70.81. The company has a market cap of $1.24 billion, a PE ratio of -106.94 and a beta of 0.74.

Insider Buying and Selling

In related news, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the sale, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at $2,943,540. This trade represents a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,781 shares of company stock valued at $2,465,372 over the last three months. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.